Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company developing therapies for immune-mediated inflammatory conditions. Its core platform involves small molecule BET inhibitors, targeting epigenetic regulators of inflammation. Key products include topical repibresib gel for vitiligo and oral VYN202 for autoimmune diseases like psoriasis. The company focuses on localized, low systemic exposure treatments, leveraging proprietary compounds and licensing agreements to address high unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.